ACES Cas: 7365-82-4 Pulvis crystallinus albus 99% N.
Catalogue Number | XD90108 |
Product Name | ACES (N-(2-Acetamido) -2-aminoethanesulfonic acid) |
CAS | 7365-82-4 |
Formulae hypotheticae | C4H10N2O4S |
M. Pondus | 182.2 |
Repono Details | Ambiens |
Tariff Code harmonized | 29241900 |
Product Specification
Plumbum | <5ppm |
pH | 3.5 - 4.5 |
Aqua Content | <0.5% |
Ferrum | <5ppm |
Residere in Ignition | <0.1% |
Aspectus | Album pulveris crystallini |
A260 (aquam 0.1M) | <0.020 |
A280 (aqua 0.1M) | <0.010 |
Temptare (Titration) in exaruit basis | >99% |
Objectum huius studii erat efficaciam valproatis versus haloperidol comparare in gradu perturbationis minuendo in aegros affectis in genere tempori.Aegentes 80 acutissime agitatos assignavimus ut vel sodium intravenosum (20 mg/kg) vel haloperidol intramuscular (5 mg/1 ml).Agitatio ad basilineum mensus est et 30 min post primam iniectionem utens Agitationis Calmitas Aestimatio Scale (ACES), Positivum et Negativa Syndrome Scale-Excitatae Componentis subscale, et Scala agitata Moribus.Pro 80 aegris cum sodio valproate curatis, media ± SD dosis erat 1541.5± 286 mg (range 940-2400).Medium postintervention ACES scores ab baseline ad 30 min post injectionem medicamentorum 4.73 (SD = 1.93) pro globo valproate et 5.45 (SD = 2.09) pro globo haloperidolorum (P = 0.028).Nullae notabiles differentiae observatae sunt in terminis mutationum mediarum 30 min post interventum pro duabus squamis agitationis additis.Maior proportio aegrorum in globus haloperidolorum sedationem intensam expertorum (36,2%, P < 0.001) et symptomata extrapyramidarum (8.7%, P = 0.007) comparata cum globo valproate (2.5% pro sedatione intensa, nulla patienti ad symptomata extrapyramidalia).Inventiones suadeant in praxi clinica occasus psychiatriae subitis, valproatus intravenae tam efficax quam haloperidol in reducendo agitatione, cum profile meliore salute.